Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: A meta-analysis

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2793-2800

  He, Hai Rong ^a   Liu, Ping ^a   He, Gong Hao ^b   Dong, Wei Hua ^a   Wang, Mao Yi ^a   Dong, Ya Lin ^a   Lu, Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KUNMING GENERAL HOSPITAL   (China)

Author keywords

Acute lymphoblastic leukemia; Methotrexate; Pharmacogenetics; Polymorphism; RFC1; Toxicity

Indexed keywords

METHOTREXATE; REDUCED FOLATE CARRIER; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD LEUKEMIA; DRUG BLOOD LEVEL; GENETIC MODEL; GENOTYPE; HUMAN; LEUKOPENIA; LIVER TOXICITY; META ANALYSIS; MUCOSA INFLAMMATION; NEUROTOXICITY; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; AGE; ALLELE; CHILD; FEMALE; GENETICS; MALE; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK;

AGE FACTORS; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; FEMALE; GENOTYPE; HUMANS; MALE; METHOTREXATE; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REDUCED FOLATE CARRIER PROTEIN;

EID: 84919449305     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.898761     Document Type: Article

References (30)

1. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-4489.
2. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2012; 13: 498-506.
3. Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 2013;121:5145-5153.
4. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151-4157.
5. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. JHum Genet 2007;52:166-171.
6. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-1043.
7. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819-834.
8. Zhao R, Diop-Bove N, Visentin M, et al. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011;31:177-201.
9. Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69:691-696.
10. Whetstine JR, Giford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001; 7: 3416-3422.
11. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G-A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310-315.
12. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006;6:117-129.
13. Aldrin M, Raastad R, Tvete IF, et al. Antibiotic resistance in hospitals: a ward-Specific random Effect model in a low antibiotic consumption environment. Stat Med 2013; 32: 1407-1418.
14. de Deus DM, de Lima EL, Seabra SR, et al. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treat 2012;2012:292043.
15. Lopez-Lopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2013;23:53-61.
16. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. P olymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:612-619.
17. Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010;27:344-354.
18. Faganel KB, Dolzan V, Grabnar I, et al. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:724-726.
19. Huang L, Tissing WJ, de Jonge R, et al. Polymorphisms in folate-related genes: association with side Effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 1798-1800.
20. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008;30:347-352.
21. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, et al. G enetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 2007;86:609-611.
22. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084-3091.
23. Faganel KB, Grabnar I, Bohanec GP, et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011;67:993-1006.
24. Gregers J, Christensen IJ, Dalhof K, et al. The association of reduced folate carrier 80G A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010; 115: 4671-4677.
25. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-3834.
26. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-68.
27. Pui CH, Evans WE. Treatmentofacute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
28. Schmiegelow K.Advancesinindividualpredictionofmethotrexate toxicity: a review. Br J Haematol 2009;146:489-503.
29. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547-566.
30. Yang L, Hu X, Xu L. Impactofmethylenetetrahydrofolatereductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012; 33: 1445-1454.